Candel Therapeutics Inc (NASDAQ: CADL) kicked off on Friday, up 4.19% from the previous trading day, before settling in for the closing price of $4.77. Over the past 52 weeks, CADL has traded in a range of $3.79-$14.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -20.00%. While this was happening, its average annual earnings per share was recorded 13.60%. With a float of $34.58 million, this company’s outstanding shares have now reached $46.93 million.
The extent of productivity of a business whose workforce counts for 38 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Candel Therapeutics Inc (CADL) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Candel Therapeutics Inc is 26.79%, while institutional ownership is 33.94%. The most recent insider transaction that took place on Mar 18 ’25, was worth 396,995. In this transaction Chief Medical Officer of this company sold 45,316 shares at a rate of $8.76, taking the stock ownership to the 52,493 shares. Before that another transaction happened on Mar 18 ’25, when Company’s Chief Scientific Officer sold 32,146 for $8.76, making the entire transaction worth $281,673. This insider now owns 96,527 shares in total.
Candel Therapeutics Inc (CADL) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.26 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 13.60% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.34% during the next five years compared to -43.86% drop over the previous five years of trading.
Candel Therapeutics Inc (NASDAQ: CADL) Trading Performance Indicators
Take a look at Candel Therapeutics Inc’s (CADL) current performance indicators. Last quarter, stock had a quick ratio of 2.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.75, a number that is poised to hit -0.37 in the next quarter and is forecasted to reach -1.87 in one year’s time.
Technical Analysis of Candel Therapeutics Inc (CADL)
The latest stats from [Candel Therapeutics Inc, CADL] show that its last 5-days average volume of 0.96 million was inferior to 1.22 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 35.42%. Additionally, its Average True Range was 0.66.
During the past 100 days, Candel Therapeutics Inc’s (CADL) raw stochastic average was set at 10.96%, which indicates a significant decrease from 16.51% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 108.68% in the past 14 days, which was lower than the 167.20% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.82, while its 200-day Moving Average is $6.64. Now, the first resistance to watch is $5.08. This is followed by the second major resistance level at $5.19. The third major resistance level sits at $5.36. If the price goes on to break the first support level at $4.80, it is likely to go to the next support level at $4.63. Assuming the price breaks the second support level, the third support level stands at $4.52.
Candel Therapeutics Inc (NASDAQ: CADL) Key Stats
The company with the Market Capitalisation of 234.78 million has total of 47,235K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -55,180 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -14,070 K.
